Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.

PloS one - 1 Jan 2012

Xia Xue, Babcock Joseph P, Blaber Sachiko I, Harper Kathleen M, Blaber Michael

Abstract excerpt

Fibroblast growth factor-1 (FGF-1) is an angiogenic factor with therapeutic potential for the treatment of ischemic disease. FGF-1 has low intrinsic thermostability and is characteristically formulated with heparin as a stabilizing agent. Heparin, however, adds a number of undesirable properties that negatively impact safety and cost. Mutations that increase the thermostability of FGF-1 may obviate the need for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Fibroblast Growth Factor 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heparan Sulfate Proteoglycans

Share to Ischemia

Share to Rabbits

Share to Recombinant Proteins

Share to Sulfhydryl Compounds

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 23133616
DOI: 10.1371/journal.pone.0048210
PMCID: PMC3486806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.PMID 23133616Read ↗

Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life.Semantic proximity Read ↗

Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action.Semantic proximity Read ↗

Bioengineering an Ultra-Stable and Cost-Effective FGF2 (NGF2) with Extended Circulatory Half-Life for Next-Generation TherapeuticsSemantic proximity Read ↗

An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.Semantic proximity Read ↗

Structural and biochemical investigation into stable FGF2 mutants with novel mutation sites and hydrophobic replacements for surface-exposed cysteines.Semantic proximity Read ↗

Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application.Semantic proximity Read ↗

A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.Semantic proximity Read ↗

Application of bioinformatics and molecular dynamics simulation approaches for identification of fibroblast growth factor 10 analogues with potentially improved thermostability.Semantic proximity Read ↗

Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.Semantic proximity Read ↗

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.Semantic proximity Read ↗

Temperature-responsive structural reversibility of FGF21 and structure-based design of its variant with enhanced potencySemantic proximity Read ↗

Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.